Jardiance Joy Boosts Boehringer Ingelheim

 
• By Eleanor Malone

Leading the pack with partner Lilly in the expansion of diabetes medication into cardiovascular protection, Boehringer Ingelheim looks set to build this year on its healthy 2016 growth. The completion of its acquisition of Sanofi's Mérial animal health business in January will also boost future sales.

Hitting bigger business target
Boehringer Ingelheim is aiming bigger in diabetes • Source: Shutterstock

More from Earnings

More from Business